• Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
  • Vect-Horus science
Overview

VECT-HORUS is a French biotechnology company focused on developing vector molecules and vectorized drug-candidates that will open new avenues for drug delivery to the central nervous system (CNS, brain and spinal cord) and treatment of CNS diseases.

VECT-HORUS’ breakthrough vector technology is dedicated to enhance drug targeting and delivery to the diseased CNS for the treatment of pathologies which represent the second therapeutic area on the pharmaceutical market in terms of sales turnover. VECT-HORUS develops vector molecules for conjugation with drugs or drug-candidates that normally cannot enter the brain.

VECT-HORUS’ strategy is to leverage its CNS drug targeting platform to create patentable New Chemical Entities (NCEs) that cross the blood brain barrier (BBB). Such compounds will be out-licensed to (bio)pharmaceutical companies once proof-of-therapeutic efficacy or preclinical proof-of-principle is established.

Read more...
 
History

VECT-HORUS is a start-up biotechnology company, spin-off of the UMR 7259 laboratory directed by Dr. Michel Khrestchatisky and supported by the CNRS and Aix-Marseille University, Marseille, France. The company was created in December 2005 within the framework of collaboration and licensing agreements with the CNRS and Aix-marseille University.

Read more...
 
Mission

With its innovative strategies in biotechnology (recombinant DNA, cell biology, screening of peptide libraries) and medicinal chemistry (prodrug, vectorization), VECT-HORUS’ mission is to discover unique vectors that target the CNS in order to promote the development of efficient treatments for major brain diseases.

Read more...
 
purple_lens.jpg

Around The World

© 2014 Vect-Horus